Wall Street brokerages forecast that AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will announce earnings of ($0.06) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for AVEO Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.10) and the highest estimate coming in at ($0.05). AVEO Pharmaceuticals posted earnings per share of ($0.15) in the same quarter last year, which indicates a positive year-over-year growth rate of 60%. The business is expected to issue its next earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that AVEO Pharmaceuticals will report full year earnings of ($0.16) per share for the current year, with EPS estimates ranging from ($0.21) to ($0.11). For the next financial year, analysts expect that the company will report earnings of ($0.15) per share, with EPS estimates ranging from ($0.18) to ($0.10). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow AVEO Pharmaceuticals.
AVEO Pharmaceuticals (NASDAQ:AVEO) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The company had revenue of $1.61 million for the quarter, compared to analyst estimates of $0.74 million. AVEO Pharmaceuticals had a negative return on equity of 24.50% and a net margin of 70.30%.
Hedge funds have recently made changes to their positions in the company. Two Sigma Securities LLC bought a new stake in AVEO Pharmaceuticals during the fourth quarter worth approximately $28,000. HCR Wealth Advisors acquired a new stake in shares of AVEO Pharmaceuticals during the 1st quarter valued at about $28,000. Excalibur Management Corp grew its position in shares of AVEO Pharmaceuticals by 363.6% during the 1st quarter. Excalibur Management Corp now owns 51,000 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 40,000 shares during the period. SG Americas Securities LLC acquired a new stake in shares of AVEO Pharmaceuticals during the 1st quarter valued at about $50,000. Finally, Rhumbline Advisers grew its position in shares of AVEO Pharmaceuticals by 50.4% during the 4th quarter. Rhumbline Advisers now owns 138,271 shares of the biopharmaceutical company’s stock valued at $221,000 after acquiring an additional 46,307 shares during the period. 28.31% of the stock is currently owned by hedge funds and other institutional investors.
AVEO Pharmaceuticals stock traded down $0.01 on Friday, hitting $0.70. The company’s stock had a trading volume of 99,774 shares, compared to its average volume of 2,679,862. The stock has a market capitalization of $115.67 million, a price-to-earnings ratio of -3.68 and a beta of 0.88. The firm has a fifty day simple moving average of $0.72. AVEO Pharmaceuticals has a one year low of $0.49 and a one year high of $3.59.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Featured Article: Asset Allocation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.